Related Articles

• In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines
• Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling
• Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer
• Mechanism of targeting the mTOR pathway to regulate ferroptosis in NSCLC with different EGFR mutations
• Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations